|
|
|
|
Eyepoint Pharmaceuticals Inc (EYPT) |
|
Price: $6.6100
$0.36 
5.760%
|
| Day's High:
| $6.67
| Week Perf:
| 7.48 %
|
| Day's Low: |
$ 5.98 |
30 Day Perf: |
-8.7 % |
| Volume (M): |
1,186 |
52 Wk High: |
$ 15.63 |
| Volume (M$): |
$ 7,837 |
52 Wk Avg: |
$6.64 |
| Open: |
$6.20 |
52 Wk Low: |
$2.19 |
|
|
| Market Capitalization (Millions $) |
253 |
| Shares
Outstanding (Millions) |
38 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
43 |
| Net Income (TTM) (Millions $) |
-100 |
| Cash Flow (TTM) (Millions $) |
58 |
| Capital Exp. (TTM) (Millions $) |
3 |
Eyepoint Pharmaceuticals Inc
Company Address: 480 Pleasant Street Watertown 2472 MA
Company Phone Number: 926-5000 Stock Exchange / Ticker: NASDAQ EYPT
| EYPT is expected to report next financial results on March 09, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) has shown impressive growth in its stock value, gaining 12.39% over the past five trading days. Additionally, despite a challenging year, the company's stock has seen a significant increase of 66.55% compared to the previous year. Furthermore, Cytek Biosciences Inc's stock currently trades 28.9% above its 52-week low. Analyzing these financial results, it becomes evident that the company has managed to battle industry headwinds and achieve notable progress. However, it is crucial to consider the company's recent fiscal performance and other factors that may impact the company's future outlook.
Fiscal Performance:
For the fiscal period ending September 30, 2023, Cytek Biosciences Inc has recorded a shortfall per share of -$0.05, compared to a positive $0.01 per share a year earlier. This represents a decline from the preceding reporting season's shortfall of -$0.03 per share. Although the company has experienced a widening shortfall, it is important to note that revenue has increased significantly.
|
|
Talis Biomedical Corporation
The latest financial results reported by Talis Biomedical Corporation for the period ending September 30, 2023, paint a bleak picture. With a significant decline in revenue and expanding net deficits, the company has announced its intention to explore strategic alternatives to maximize shareholder value. This article will delve into the impact these results may have on the company's future prospects.
Dismal Revenue and Widening Deficit:
Talis Biomedical Corporation witnessed a staggering 82.412% decline in revenue compared to the same reporting period last year, earning only $0.14 million. This follows a 75.904% revenue drop from the previous reporting period, where the company generated $0.58 million. These figures indicate a concerning trend of declining sales.
|
|
Singular Genomics Systems Inc
The Laboratory Analytical Instruments company, Singular Genomics Systems Inc, reported limited revenue of only $0.462 million in the third quarter of 2023. Moreover, the company experienced a net loss of an alarming $-22.360 million in the same quarter, a significant deterioration compared to the previous year's deficit of $-23.790 million. Furthermore, inventories have declined to $13.4 million, indicating potential weakening future demand. These factors, coupled with other concerning indicators, suggest a bearish outlook for Singular Genomics Systems Inc.
Declining Inventories Reflect Lower Demand:
A critical aspect to assess a company's growth prospects lies in its inventory levels, which provide insight into future demand. Singular Genomics Systems Inc witnessed a decline in inventories to $13.4 million in the third quarter, compared to the previous quarter as well as the same period a year before. This reduction raises concerns about weakening demand and potential challenges the company may face in generating future revenue.
|
|
Illumina Inc
Illumina Inc, a Laboratory Analytical Instruments company, experienced a challenging third quarter in 2023, reporting a loss of $-4.77 per share. This marked an improvement from the previous year, where the loss per share was significantly higher at $-24.26.
Interestingly, while most companies in the Laboratory Analytical Instruments sector saw a decline in revenue, Illumina Inc managed to achieve a slight growth of 0.359%. The company's revenue reached $1.12 billion during the quarter, compared to $1.12 billion in the same period the previous year. However, there was a sequential decrease in revenue of -4.847% from $1.18 billion.
|
|
Astrotech Corp
Astrotech Corp is a company operating in the Laboratory Analytical Instruments sector that has experienced strong revenue growth in the first quarter of the 2024 earnings season. Despite this positive revenue increase of 1018.421% year on year to $0.43 million, the company also saw a significant increase in its deficit per share at $-1.79.
In comparison to the previous quarter, there was an increase in the deficit per share from $-1.44 and a revenue increase of 2.657% from $0.41 million. This suggests that Astrotech Corp is performing well relative to other companies in the same sector, as many have been affected by receding transactions and declining top-line figures.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.45 $ |
| Revenues (TTM) |
1.11 $
|
| Cash Flow (TTM) |
1.5 $ |
| Cash |
3.55 $
|
| Book Value |
1.53 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.45 $
|
| Revenues (TTM) |
1.11 $ |
| Cash Flow (TTM) |
1.5 $ |
| Cash |
3.55 $
|
| Book Value |
1.53 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
